Medlive Technology Co., Ltd. (2192) AI Stock Analysis

• Market Cap: HK$10.87B
• Dividend Yield: 1.86%
• Average Volume (3M): 2.72M
• Price to Earnings (P/E): 31.6
• Beta (1Y): 1.44
• Revenue Growth: 33.41%
• EPS Growth: 26.81%
• Country: HK
• Employees: 747
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Distribution
• EPS (TTM): 0.25
• Shares Outstanding: 734,258,850
• 10 Day Avg. Volume: 3,106,750
• 30 Day Avg. Volume: 2,722,839
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$16.50
• Price Target Upside: 9.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 72 Outperform
• Price Target: HK$16.50 ▲(9.71% Upside)

Medlive Technology Co., Ltd. exhibits strong financial performance with robust revenue growth and a solid balance sheet. However, the stock's valuation appears high, and technical indicators suggest neutral momentum. These factors contribute to a moderate overall stock score.

Medlive Technology Co., Ltd. Business Overview & Revenue Model

Company Description

Medlive Technology Co., Ltd., together with its subsidiaries, operates an online professional physician platform in Mainland China and internationally. Its precision marketing and corporate solution provides full service on its one-site platform, which includes project management, clinical monitoring, clinical data management, biostatistics, protocol design, medical monitoring, patient recruitment, and supporting system, as well as digital market research, electronic data capture, real-world studies, and application software development services. The company's medical knowledge solution offers medical education and clinical decision support, including licensing software to physicians, other registered users, such as other healthcare professionals and pharmaceutical companies. Its intelligent patient management solution provides chronic disease management services, comprising online patient consultation, prescription services, and patient management through Internet hospital; and condition-specific patient education services, which includes content development, application software development, and other related services. The company was formerly known as Kingyee Co., Limited and changed its name to Medlive Technology Co., Ltd. in 2021. Medlive Technology Co., Ltd. was founded in 1996 and is headquartered in Beijing, China.

How the Company Makes Money

Medlive Technology Co., Ltd. generates revenue through a combination of subscription fees, advertising, and partnership arrangements. Key revenue streams include subscription services for access to premium medical content and tools, which are utilized by healthcare professionals and institutions. The company also earns income from pharmaceutical and medical device companies through targeted advertising and sponsored content, which allow these firms to reach a highly specialized audience. Additionally, Medlive engages in partnerships with healthcare organizations to offer customized solutions and services, further contributing to its financial performance.

Medlive Technology Co., Ltd. Financial Statement Overview

Summary

Medlive Technology Co., Ltd. demonstrates robust financial performance with strong revenue growth, stable gross and net profit margins, and a solid balance sheet with low leverage. The company also maintains healthy cash flows, despite some variability in investment activities.

Income Statement

Medlive Technology Co., Ltd. demonstrates robust revenue growth, with Total Revenue increasing from 2019 to 2024. The Gross Profit Margin and Net Profit Margin have remained strong, reflecting stable and efficient cost management. Despite a decline in EBIT Margin from previous years, the EBITDA Margin remains healthy, indicating strong operational performance.

Balance Sheet

The company's Balance Sheet is solid with a high Equity Ratio, suggesting financial stability and low reliance on debt. The Debt-to-Equity Ratio is very low, indicative of minimal financial leverage. Return on Equity has shown a positive trend, highlighting effective use of shareholder funds.

Cash Flow

Cash flow analysis reveals consistent Free Cash Flow generation, with positive growth over time. The Operating Cash Flow to Net Income Ratio indicates strong cash-generating capability. However, fluctuations in Investing Cash Flow suggest potential volatility in investment activities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	558.46M	412.00M	314.05M	284.44M	213.53M
Gross Profit	327.22M	251.34M	212.74M	200.73M	156.24M
EBITDA	121.35M	262.86M	144.56M	76.61M	110.37M
Net Income	315.15M	242.30M	117.32M	40.62M	85.20M
Balance Sheet
Total Assets	5.11B	4.89B	4.60B	4.12B	227.06M
Cash, Cash Equivalents and Short-Term Investments	4.15B	4.40B	4.22B	3.91B	147.09M
Total Debt	22.63M	8.19M	11.26M	13.17M	12.07M
Total Liabilities	253.56M	248.61M	171.31M	143.37M	75.64M
Stockholders Equity	4.80B	4.60B	4.40B	3.95B	151.41M
Cash Flow
Free Cash Flow	87.44M	69.34M	69.70M	42.47M	110.42M
Operating Cash Flow	108.32M	101.87M	77.19M	44.43M	111.05M
Investing Cash Flow	111.02M	-634.95M	-3.59B	-50.54M	13.00K
Financing Cash Flow	-197.89M	-133.13M	-22.38M	3.79B	-2.83M

Medlive Technology Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2192, the sentiment is Positive. The current price of 15.04 is above the 20-day moving average (MA) of 15.03, above the 50-day MA of 15.04, and above the 200-day MA of 11.98, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.82 is Neutral, neither overbought nor oversold. The STOCH value of 34.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2192.

Medlive Technology Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2192	72 Outperform	HK$10.87B	31.60	6.72%	1.86%	33.41%	26.81%
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.82%	-2.28%
SHPMF	―	$8.84B	9.74	6.08%	3.31%	―	―
SHTDF	―	$7.72B	7.33	9.19%	4.10%	―	―
1931	67 Neutral	HK$14.01B	45.76	7.40%	1.06%	0.67%	-1.75%
9955	47 Neutral	HK$984.46M	―	-31.49%	―	-7.28%	-46.18%
2289	―	HK$630.72M	10.92	8.78%	8.16%	―	―

Medlive Technology Co., Ltd. Corporate Events

Medlive Technology Updates Nomination Committee Terms

Medlive Technology Co., Ltd. has updated the terms of reference for its Nomination Committee, effective from June 30, 2025. The committee, which will consist of at least three directors with a majority being independent non-executive directors, is tasked with reviewing the board’s structure and composition annually. This move aims to ensure the board’s alignment with the company’s corporate strategy and enhance its governance by selecting qualified individuals for directorships.

Medlive Technology Co., Ltd. Successfully Concludes Annual General Meeting with Key Resolutions Passed

Medlive Technology Co., Ltd. held its Annual General Meeting on May 8, 2025, where all proposed resolutions were approved by shareholders. Key outcomes included the re-election of directors, the declaration of a final dividend for 2024, and the approval of mandates for share repurchase and issuance, indicating strong shareholder support and strategic direction for the company’s future operations.